These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1379106)

  • 21. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
    Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
    Kaplan SA; Reis RB; Cologna A; Suaid HJ; Martins AC; Kohn IJ; Te AE
    Urology; 1998 Jul; 52(1):12-6. PubMed ID: 9671862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The treatment of patients with benign prostatic hyperplasia using the selective alpha-blocker alfuzosin].
    Mazo EB; Matushevskiĭ IA; Nikitin IuIu
    Ter Arkh; 1997; 69(10):79-82. PubMed ID: 9471799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
    Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
    Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
    Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
    Eur Urol; 1995; 27(2):128-34. PubMed ID: 7538083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group.
    Hansen BJ; Flyger H; Mortensen S; Mensink HJ; Meyhoff HH
    Scand J Urol Nephrol; 1996 Apr; 30(2):103-7. PubMed ID: 8738054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction.
    Buzelin JM; Delauche-Cavallier MC; Roth S; Geffriaud-Ricouard C; Santoni JP
    Br J Urol; 1997 Jun; 79(6):898-904; discussion 904-6. PubMed ID: 9202556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alfuzosin: a clinically uroselective alpha1-blocker.
    Höfner K; Jonas U
    World J Urol; 2002 Apr; 19(6):405-12. PubMed ID: 12022709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
    McNeill SA; Hargreave TB; Roehrborn CG;
    Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.
    Kaplan SA; Gonzalez RR; Te AE
    Eur Urol; 2007 Jun; 51(6):1717-23. PubMed ID: 17258855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of alfuzosin treatment in patients with prostatism.
    Başar MM; Atan A; Ozergin O; Yildiz M
    Int Urol Nephrol; 2001; 33(3):493-7. PubMed ID: 12230279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Safety ov benign prostatic hyperplasia treatment with alpha-adrenoblocker dalphas].
    Loran OB; Pushkar' DIu; Rasner PI
    Urologiia; 2000; (2):3-5. PubMed ID: 11186726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pressure-flow changes after long-term treatment with alfuzosin SR.
    De Nunzio C; Franco G; Iori F; Leonardo C; Minardi V; Laurenti C
    Urol Int; 2003; 71(1):31-6. PubMed ID: 12845257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alfuzosin for benign prostatic hypertrophy.
    Chapple CR
    Lancet; 1991 Jul; 338(8760):182. PubMed ID: 1712882
    [No Abstract]   [Full Text] [Related]  

  • 37. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
    Rosen R; Seftel A; Roehrborn CG
    Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urodynamic and clinical effect of alpha-adrenergic blocker (phenoxybenzamine) in patients with benign prostatic hyperplasia.
    Chen KK; Chang LS; Chen MT; Huang JK; Yin JH; Lin SN; Lin AD
    Zhonghua Yi Xue Za Zhi (Taipei); 1988 Feb; 41(2):127-30. PubMed ID: 2458811
    [No Abstract]   [Full Text] [Related]  

  • 40. A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial.
    Lapitan MC; Acepcion V; Mangubat J
    J Int Med Res; 2005; 33(5):562-73. PubMed ID: 16222890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.